Reversing cachexia


Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

Publication DOI:
Divisions: Life & Health Sciences > Pharmacy
Life & Health Sciences
Life & Health Sciences > Chronic and Communicable Conditions
Uncontrolled Keywords: Biochemistry, Genetics and Molecular Biology(all)
Full Text Link: https://www.sci ... 8998?via%3Dihub
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Article
Published Date: 2010-08-20
Authors: Tisdale, Michael J.

Export / Share Citation


Additional statistics for this record